Health Economics›Classical Hodgkin lymphoma›Relapsed or refractory further lines of therapy

Relapsed or refractory further lines of therapy

Classical Hodgkin lymphoma · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Sirolimus and Vorinostat Variant #01 Partial	—	R 15 126	28d	—	—	—	—	—
Doxorubicin and Lomustine Variant #01 Partial	—	R 1 006	42d	—	—	—	—	—
Panobinostat monotherapy Variant #01 Partial	—	—	21d	—	—	—	—	—
Carmustine monotherapy Variant #01 Partial	—	—	42d	—	—	—	—	—

4 of 4 regimens shown